CD47 and neoplasm: Recent preclinical models and clinical trials have explored therapeutic targeting of CD47, which has shown promising results for B cell lymphoma when combined with tumor-targeting antibodies [5]. However, addressing the CD47 antigen sink and limited therapeutic activity observed in solid tumors remains challenging.